COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective
Introduction: The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about whether to get vaccinated or not. Here, we evaluated attitude towards and effects of COVID-19 vaccinati...
Guardado en:
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c56b223aaf9545459022a504855c2e26 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:c56b223aaf9545459022a504855c2e26 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:c56b223aaf9545459022a504855c2e262021-11-04T04:26:25ZCOVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective1532-308010.1016/j.breast.2021.10.012https://doaj.org/article/c56b223aaf9545459022a504855c2e262021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0960977621009826https://doaj.org/toc/1532-3080Introduction: The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about whether to get vaccinated or not. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast and gynecological cancer undergoing systemic cancer therapy. Methods: Since March 15th, 2021, cancer patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate and late side effects. Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to vaccination were documented. The collected data were analyzed de-identified as a part of routine quality assurance. Results: By July 27th, 2021, 218 patients (74.3% breast cancer patients) had received one of two COVID-19 vaccine doses, and 112 patients had received both doses: 77.5% received Conmirnaty (BioNTech/Pfizer), 16.1% Vaxzevria (Astra Zeneca) and 5.9% COVID-19 Vaccine Moderna. The COVID-19 vaccines had an acceptable safety profile with self-limiting local and systemic adverse events, which rarely lasted >48 h post vaccination. Symptoms occurred predominantly after the second dose of the vaccine and less frequently in older patients >55 years. No vaccine-related serious adverse events were reported, and only limited effects of vaccination on the therapy schedule were observed. Conclusions: Breast and gynecologic cancer patients tolerate the COVID-19 vaccination while undergoing systemic cancer therapy without any additional side effects beyond those reported in the general population.Marie ForsterRachel WuerstleinAlexander KoenigNiklas AmannSusanne BeyerTill KaltofenTom DegenhardtAlexander BurgesFabian TrillschSven MahnerNadia HarbeckAnca Chelariu-RaicuElsevierarticleCOVID-19VaccinationCancer patientsBreast cancerGynecological cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast, Vol 60, Iss , Pp 214-222 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
COVID-19 Vaccination Cancer patients Breast cancer Gynecological cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
COVID-19 Vaccination Cancer patients Breast cancer Gynecological cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Marie Forster Rachel Wuerstlein Alexander Koenig Niklas Amann Susanne Beyer Till Kaltofen Tom Degenhardt Alexander Burges Fabian Trillsch Sven Mahner Nadia Harbeck Anca Chelariu-Raicu COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective |
description |
Introduction: The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about whether to get vaccinated or not. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast and gynecological cancer undergoing systemic cancer therapy. Methods: Since March 15th, 2021, cancer patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate and late side effects. Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to vaccination were documented. The collected data were analyzed de-identified as a part of routine quality assurance. Results: By July 27th, 2021, 218 patients (74.3% breast cancer patients) had received one of two COVID-19 vaccine doses, and 112 patients had received both doses: 77.5% received Conmirnaty (BioNTech/Pfizer), 16.1% Vaxzevria (Astra Zeneca) and 5.9% COVID-19 Vaccine Moderna. The COVID-19 vaccines had an acceptable safety profile with self-limiting local and systemic adverse events, which rarely lasted >48 h post vaccination. Symptoms occurred predominantly after the second dose of the vaccine and less frequently in older patients >55 years. No vaccine-related serious adverse events were reported, and only limited effects of vaccination on the therapy schedule were observed. Conclusions: Breast and gynecologic cancer patients tolerate the COVID-19 vaccination while undergoing systemic cancer therapy without any additional side effects beyond those reported in the general population. |
format |
article |
author |
Marie Forster Rachel Wuerstlein Alexander Koenig Niklas Amann Susanne Beyer Till Kaltofen Tom Degenhardt Alexander Burges Fabian Trillsch Sven Mahner Nadia Harbeck Anca Chelariu-Raicu |
author_facet |
Marie Forster Rachel Wuerstlein Alexander Koenig Niklas Amann Susanne Beyer Till Kaltofen Tom Degenhardt Alexander Burges Fabian Trillsch Sven Mahner Nadia Harbeck Anca Chelariu-Raicu |
author_sort |
Marie Forster |
title |
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective |
title_short |
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective |
title_full |
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective |
title_fullStr |
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective |
title_full_unstemmed |
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective |
title_sort |
covid-19 vaccination in patients with breast cancer and gynecological malignancies: a german perspective |
publisher |
Elsevier |
publishDate |
2021 |
url |
https://doaj.org/article/c56b223aaf9545459022a504855c2e26 |
work_keys_str_mv |
AT marieforster covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT rachelwuerstlein covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT alexanderkoenig covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT niklasamann covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT susannebeyer covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT tillkaltofen covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT tomdegenhardt covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT alexanderburges covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT fabiantrillsch covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT svenmahner covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT nadiaharbeck covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective AT ancachelariuraicu covid19vaccinationinpatientswithbreastcancerandgynecologicalmalignanciesagermanperspective |
_version_ |
1718445299967459328 |